Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 23, 2025Frontiers in ImmunologyOpen Access

Biochemical markers and emerging therapies for intestinal manifestation of graft-versus-host disease

View Full Paper
Ask AI
Bookmark
Share

Authors

KWKatarzyna WiejakAPAdam PrzybyłkowskiATAgnieszka Tomaszewska

Discussion

Loading...

Member takes

Overview

This review highlights biomarkers and emerging therapies for gastrointestinal involvement in graft-versus-host disease, indicating challenges in diagnosis and treatment.

Key Points

  • Graft-versus-host disease (GVHD) significantly complicates outcomes after allogeneic hematopoietic stem cell transplantation.
  • Gastrointestinal GVHD correlates with a poorer prognosis, highlighting the need for better diagnostic and therapeutic strategies.
  • REG3α and ST2 are among the most promising biomarkers, though their comprehensive validation for GVHD is still required.
  • Emerging treatments for GVHD show potential, but additional research is necessary to explore new therapeutic targets in the gastrointestinal tract.

Cite This Study

Wiejak et al. (2025) studied this question.

synapsesocial.com/papers/68d43ed1713b0b5dfea7e027https://doi.org/10.3389/fimmu.2025.1645503
View Full Paper
Ask AI
Bookmark
Share